Floatz logo

FLORTAUCIPIR

PPA

Mayo ClinicSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the PPA cohort.

Asset / SponsorPhaseRating
Rotigotine
I.R.C.C.S. Fondazione Santa Lucia
Phase 2B
Nabilone
Simon Ducharme, MD
Phase 2CCC
FLUDEOXYGLUCOSE
Mayo Clinic
Phase 1CC
PITTSBURGH COMPOUND B UNLABELLED
Mayo Clinic
Phase 1CC
FLORTAUCIPIR
Mayo Clinic
Phase 1CC

View all 9 →

Same molecule, other indications

FLORTAUCIPIR is also rated in:

Alzheimer diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
frontotemporal dementiaDormant
BBB
Indicative ·
73 / 100
View asset →
progressive non-fluent aphasiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →